The Scientist

» polar research, evolution and disease/medicine

Most Recent

Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.

1 Comment

image: Contributors

Contributors

By | June 1, 2016

Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.

0 Comments

image: Start Making Sense

Start Making Sense

By | June 1, 2016

Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.

6 Comments

image: Toward Targeted Therapies for Autoimmune Disorders

Toward Targeted Therapies for Autoimmune Disorders

By | June 1, 2016

Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.

2 Comments

Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.

1 Comment

image: FDA Approves Bladder Cancer Immunotherapy

FDA Approves Bladder Cancer Immunotherapy

By | May 23, 2016

Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.

0 Comments

Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.

1 Comment

image: Genome Digest

Genome Digest

By | May 17, 2016

Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.

0 Comments

image: Genetic Connections Among Human Traits

Genetic Connections Among Human Traits

By | May 16, 2016

Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.

0 Comments

image: Mysterious Eukaryote Missing Mitochondria

Mysterious Eukaryote Missing Mitochondria

By | May 12, 2016

Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.

5 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech